AtriCure
ATRC
108 hedge funds and large institutions have $630M invested in AtriCure in 2018 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 47 reducing their positions, and 12 closing their positions.
14% more capital invested
Capital invested by funds: $552M → $630M (+$78.3M)
1.09% more ownership
Funds ownership: 87.73% → 88.82% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less funds holding
Funds holding: 109 → 108 (-1)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
32% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.9M |
| 2 |
HEC
Hudson Executive Capital
New York
|
+$6.65M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$5.07M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$3.95M |
| 5 |
Millennium Management
New York
|
+$2.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$19.2M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$4.48M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.12M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$2.75M |
| 5 |
BlackRock
New York
|
-$1.99M |
ATRC Hedge Fund Activity: Q1 2018 in Review
108 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q1 2018, worth a combined $630M — up 14% from $552M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ATRC and 11 opened new positions — a net loss of 1 holder — while 47 trimmed existing stakes and 32 added.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $26.9M. The largest seller was Victory Capital Management, cutting an estimated $19.2M.
- 108 institutional investors held AtriCure (ATRC) as of Q1 2018, down from 109 in Q4 2017.
- Funds reported $630M of AtriCure stock for Q1 2018, up 14% quarter-over-quarter.
- 11 funds opened new AtriCure positions in Q1 2018 and 12 closed out, a net change of -1 holder.
- The largest AtriCure buyer in Q1 2018 was T. Rowe Price Associates, an estimated $26.9M added.
- The largest AtriCure seller in Q1 2018 was Victory Capital Management, an estimated $19.2M sold.
Based on aggregated 13F filings for Q1 2018.